Emblaveo was jointly developed with Pfizer. AbbVie holds U.S. and Canada commercialization rights, with Pfizer responsible for commercialization in all other areas. Last April, the European Commission granted marketing authorization for treatment of adults with complicated intra-abdominal infections,

AbbVie (NYSE:ABBV) said it has received FDA approval for the intravenous antibiotic treatment Emblaveo, which was co-developed with Pfizer (NYSE:PFE). The FDA approved Emblaveo, a combination of aztreonam and avibactam,